FDA approves breakthrough drug that reduces risk of contracting HIV by 96 percent
The Food and Drug Administration has approved a breakthrough medication that reduces the risk of contracting HIV by 96 percent. Gilead’s Yeztugo, generic name lenacapavir (LEN), has been approved for prevention after highly successful trials in September found that it nearly eliminated the spread of the virus among patients, showing a 96 percent relative risk reduction versus bHIV. The drug had already been approved for treatment of multidrug-resistant HIV. The drug is meant to be given as an injection by health care workers in clinics every six months. It is currently priced at $14,109 per injection, or $2,352 per month, according to NBC News, making it unclear […]